{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T22:16:24Z","timestamp":1789856184679,"version":"4.0.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1016\/j.nano.2011.03.004","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T17:45:39Z","timestamp":1301507139000},"page":"955-964","source":"Crossref","is-referenced-by-count":86,"title":["Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes"],"prefix":"10.1016","volume":"7","author":[{"given":"Monica","family":"Marra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Salzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Leonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Scarsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zappavigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Calimeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Liguori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Cigliana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Ascani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Immacolata","family":"La Rotonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierosandro","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2011.03.004_bb0005","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/jbmr.5650101008","article-title":"Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo","volume":"10","author":"Hughes","year":"1995","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nano.2011.03.004_bb0010","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","article-title":"Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity","volume":"98","author":"Shipman","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.nano.2011.03.004_bb0015","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.leu.2400892","article-title":"In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates","volume":"12","author":"Aparicio","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.nano.2011.03.004_bb0020","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nano.2011.03.004_bb0025","first-page":"2602","article-title":"Bisphosphonate treatment inhibits the growth of prostate cancer cells","volume":"61","author":"Lee","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2011.03.004_bb0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/1389450053765833","article-title":"Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications","volume":"6","author":"Caraglia","year":"2005","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.nano.2011.03.004_bb0035","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/0092-8674(89)90054-8","article-title":"All Ras proteins are polyisoprenylated but only some are palmitoylated","volume":"57","author":"Hancock","year":"1989","journal-title":"Cell"},{"key":"10.1016\/j.nano.2011.03.004_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(01)00412-8","article-title":"Rho signals to cell growth and apoptosis","volume":"165","author":"Aznar","year":"2001","journal-title":"Cancer Lett"},{"key":"10.1016\/j.nano.2011.03.004_bb0045","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jcp.20960","article-title":"R115777 (Zarnestra)\/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk\/Akt inactivation and reduced Bcl-2 and bad phosphorylation","volume":"211","author":"Caraglia","year":"2007","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.nano.2011.03.004_bb0050","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.1038\/sj.onc.1207814","article-title":"The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate","volume":"23","author":"Caraglia","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.nano.2011.03.004_bb0055","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0959-8049(02)00166-1","article-title":"Farnesyl transferase inhibitors as anticancer agents","volume":"38","author":"Haluska","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nano.2011.03.004_bb0060","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2401770","article-title":"Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines","volume":"14","author":"Tassone","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.nano.2011.03.004_bb0065","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2174\/156800909789760285","article-title":"Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects","volume":"9","author":"Marra","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.nano.2011.03.004_bb0070","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2011.03.004_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14656560903485664","article-title":"Zoledronic acid: an unending tale for an antiresorptive agent","volume":"11","author":"Caraglia","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.nano.2011.03.004_bb0080","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/jjco\/hyp122","article-title":"A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy","volume":"39","author":"Miwa","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.nano.2011.03.004_bb0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1081\/LPR-120004780","article-title":"Clodronate liposomes: perspectives in research and therapeutics","volume":"12","author":"van Rooijen","year":"2002","journal-title":"J Liposome Res"},{"key":"10.1016\/j.nano.2011.03.004_bb0090","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1161\/01.CIR.0000097002.69209.CD","article-title":"Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits","volume":"108","author":"Danenberg","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.nano.2011.03.004_bb0095","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2011.03.004_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1517\/17425247.5.1.25","article-title":"Liposomal nanomedicines","volume":"5","author":"Fenske","year":"2008","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.nano.2011.03.004_bb0105","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.1998.16.7.2445","article-title":"Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial","volume":"16","author":"Northfelt","year":"1998","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.nano.2011.03.004_bb0110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1179\/joc.2004.16.Supplement-1.94","article-title":"From conventional to stealth liposomes: a new Frontier in cancer chemotherapy","volume":"16","author":"Cattel","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.nano.2011.03.004_bb0115","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.75.9.4194","article-title":"Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation","volume":"75","author":"Szoka","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2011.03.004_bb0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0003-2697(80)90269-9","article-title":"Colorimetric determination of phospholipids with ammonium ferrothiocyanate","volume":"104","author":"Stewart","year":"1980","journal-title":"Anal Biochem"},{"key":"10.1016\/j.nano.2011.03.004_bb0125","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1182\/blood-2004-03-0963","article-title":"Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells","volume":"104","author":"Tassone","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.nano.2011.03.004_bb0130","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nano.2011.03.004_bb0135","first-page":"1145","article-title":"A preclinical model for experimental chemotherapy of human head and neck cancer","volume":"18","author":"Sommer","year":"2001","journal-title":"Int J Oncol"},{"key":"10.1016\/j.nano.2011.03.004_bb0140","first-page":"401","article-title":"Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma","volume":"143","author":"Weidner","year":"1993","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nano.2011.03.004_bb0145","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.nano.2011.03.004_bb0150","doi-asserted-by":"crossref","first-page":"854","DOI":"10.2174\/156800909789760393","article-title":"Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy","volume":"9","author":"Tassone","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.nano.2011.03.004_bb0155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1476-5381.2009.00160.x","article-title":"Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro","volume":"157","author":"R\u00e4ikk\u00f6nen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nano.2011.03.004_bb0160","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/sj.bjc.6600297","article-title":"The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells","volume":"86","author":"Senaratne","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nano.2011.03.004_bb0165","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1007\/s10495-008-0211-z","article-title":"The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis","volume":"13","author":"Sewing","year":"2008","journal-title":"Apoptosis"},{"key":"10.1016\/j.nano.2011.03.004_bb0170","first-page":"2949","article-title":"Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases","volume":"60","author":"Boissier","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2011.03.004_bb0175","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nano.2011.03.004_bb0180","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nano.2011.03.004_bb0185","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2011.03.004_bb0190","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1172\/JCI200422087","article-title":"An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis","volume":"114","author":"Giraudo","year":"2004","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nano.2011.03.004_bb0195","doi-asserted-by":"crossref","first-page":"824","DOI":"10.2174\/156800909789760267","article-title":"Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials","volume":"9","author":"Gnant","year":"2009","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.nano.2011.03.004_bb0200","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.nano.2011.03.004_bb0205","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/0091270002239824","article-title":"The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function","volume":"43","author":"Skerjanec","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.nano.2011.03.004_bb0210","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1124\/dmd.108.021071","article-title":"Biodistribution and plasma protein binding of zoledronic acid","volume":"36","author":"Weiss","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.nano.2011.03.004_bb0215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-60327-360-2_13","article-title":"Liposomes for specific depletion of macrophages from organs and tissues","volume":"605","author":"van Rooijen","year":"2010","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.nano.2011.03.004_bb0220","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0005-2736(94)90038-8","article-title":"Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes","volume":"1190","author":"Litzinger","year":"1994","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nano.2011.03.004_bb0225","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0939-6411(00)00127-2","article-title":"Effect of pH, ionic strength and oxygen burden on the chemical stability of EPC\/cholesterol liposomes under accelerated conditions. Part 1: lipid hydrolysis","volume":"50","author":"Zhang","year":"2000","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nano.2011.03.004_bb0230","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/mol.105.020776","article-title":"Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis","volume":"69","author":"Thompson","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.nano.2011.03.004_bb0235","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tr\u00e9dan","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nano.2011.03.004_bb0240","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1756-8722-3-26","article-title":"Angiogenesis inhibitors in the treatment of prostate cancer","volume":"3","author":"Hwang","year":"2010","journal-title":"J Hematol Oncol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411001018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963411001018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T21:26:45Z","timestamp":1543872405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963411001018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["S1549963411001018"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2011.03.004","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}